Share on StockTwits

Jazz Pharmaceuticals plc - (NASDAQ:JAZZ) CMO Jeffrey K. Tobias sold 4,933 shares of the stock on the open market in a transaction that occurred on Monday, August 11th. The shares were sold at an average price of $135.42, for a total value of $668,026.86. Following the completion of the transaction, the chief marketing officer now directly owns 42,538 shares of the company’s stock, valued at approximately $5,760,496. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) traded up 8.81% on Wednesday, hitting $144.23. 2,021,895 shares of the company’s stock traded hands. Jazz Pharmaceuticals plc – has a 52 week low of $77.25 and a 52 week high of $176.60. The stock has a 50-day moving average of $145.4 and a 200-day moving average of $144.8. The company has a market cap of $8.686 billion and a P/E ratio of 97.97.

Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $2.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.92 by $0.13. The company had revenue of $291.23 million for the quarter, compared to the consensus estimate of $273.39 million. During the same quarter in the previous year, the company posted $1.43 earnings per share. The company’s revenue for the quarter was up 39.8% on a year-over-year basis. On average, analysts predict that Jazz Pharmaceuticals plc – will post $8.18 earnings per share for the current fiscal year.

JAZZ has been the subject of a number of recent research reports. Analysts at Zacks reiterated a “neutral” rating on shares of Jazz Pharmaceuticals plc – in a research note on Thursday, August 7th. They now have a $150.00 price target on the stock. Separately, analysts at Piper Jaffray raised their price target on shares of Jazz Pharmaceuticals plc – from $200.00 to $208.00 in a research note on Wednesday, August 6th. Finally, analysts at FBR Capital Markets cut their price target on shares of Jazz Pharmaceuticals plc – from $214.00 to $213.00 in a research note on Wednesday, August 6th. Six investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $174.05.

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry.

Receive News & Ratings for Jazz Pharmaceuticals plc - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals plc - and related companies with Analyst Ratings Network's FREE daily email newsletter.